Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Small Cell Lung Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Small Cell Lung Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
ASCO 2017 Highlights
ASCO President Urges Oncology Providers to Prioritize Education, Care Delivery, Survivorship Care
By
Wayne Kuznar
ASCO 2017 Highlights
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
Alternative Payment Models and the Dangers of 2-Sided Risk
By
Chase Doyle
ASCO 2017 Highlights
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
Alternative Payment Models May Drastically Affect Drug Manufacturers, Reduce Innovation
By
Chase Doyle
ASCO 2017 Highlights
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
Business of Practice 2017: Maximize Your MIPS Success
By
Chase Doyle
;
Chase Doyle
ASCO 2017 Highlights
,
Reimbursement
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
Improving Communication Skills to Address Patient Goals Related to End-of-Life Care
By
Chase Doyle
ASCO 2017 Highlights
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
FDA Perspective on Safety Reporting of Serious Adverse Events
By
Chase Doyle
ASCO 2017 Highlights
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
By
Phoebe Starr
ASCO 2017 Highlights
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
Pembrolizumab Makes Inroads in Sarcoma Subtypes
By
Phoebe Starr
ASCO 2017 Highlights
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
Abiraterone a Game-Changer in the Frontline Treatment of Advanced Prostate Cancer
By
Wayne Kuznar
ASCO 2017 Highlights
August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017
Read More ›
ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year
By
Eileen Koutnik-Fotopoulos
ASCO 2017 Highlights
,
Immunotherapy
July 2017, Vol 7, No 7
Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016.
Read More ›
